Innate Pharma SA logo

Innate Pharma SANASDAQ: IPHA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

17 October 2019

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$151.78 M
-67%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector
-35%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.88-$0.02(-0.85%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

IPHA Latest News

Innate Pharma Announces Its Participation in Upcoming Investor Conferences
businesswire.com29 October 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
businesswire.com14 October 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vi.

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript
seekingalpha.com12 September 2024 Sentiment: POSITIVE

Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2024 Earnings Conference Call September 12, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Rajan Sharma - Goldman Sachs Daina Graybosch - Leerink Partners Ashiq Mubarack - Citi Swayampakula Ramakanth - HCW Operator Thank you for standing by, and welcome to the Innate Pharma First-Half 2024 Financial Results and Business Update.

Innate Pharma Reports First Half 2024 Business Update and Financial Results
businesswire.com12 September 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2024. The consolidated financial statements are attached to this press release. “We are focused on our growth strategy as we advance our pipeline,” said Hervé Brailly, Chief Executive Officer ad interim of Innate Pharma. “We recently presented Phase 2 results with lacutamab in myc.

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
businesswire.com05 September 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice.

Innate Pharma Announces Its Participation in Upcoming Investor Conference
businesswire.com01 August 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conference.

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
businesswire.com04 June 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients (n=107) received a median of 4 prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatme.

Innate Pharma Announces Its Participation in Upcoming Investor Conferences
businesswire.com28 May 2024 Sentiment: NEUTRAL

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
businesswire.com24 May 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate's drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. ASCO abstract details: Lacutamab Abstract: 7082 Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from t.

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Zacks Investment Research10 April 2024 Sentiment: POSITIVE

Innate Pharma (IPHA) has received a Zacks Rank #2 (Buy), indicating increasing confidence in the company's potential earnings growth. This could lead to a rise in the stock price in the short run.

  • 1(current)

What type of business is Innate Pharma SA?

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

What sector is Innate Pharma SA in?

Innate Pharma SA is in the Healthcare sector

What industry is Innate Pharma SA in?

Innate Pharma SA is in the Biotechnology industry

What country is Innate Pharma SA from?

Innate Pharma SA is headquartered in France

When did Innate Pharma SA go public?

Innate Pharma SA initial public offering (IPO) was on 17 October 2019

What is Innate Pharma SA website?

https://www.innate-pharma.com

Is Innate Pharma SA in the S&P 500?

No, Innate Pharma SA is not included in the S&P 500 index

Is Innate Pharma SA in the NASDAQ 100?

No, Innate Pharma SA is not included in the NASDAQ 100 index

Is Innate Pharma SA in the Dow Jones?

No, Innate Pharma SA is not included in the Dow Jones index

When was Innate Pharma SA the previous earnings report?

No data

When does Innate Pharma SA earnings report?

The next expected earnings date for Innate Pharma SA is 14 November 2024